David A. Siegel Arcus Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 43,300 shares of RCUS stock, worth $633,046. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,300

Previous 38,100 13.65%

Holding current value

$633,046

Previous $580,000 14.14%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $71,188 - $93,652	5,200 Added 13.65%	43,300 $662,000
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $185,293 - $234,696	-12,700 Reduced 25.0%	38,100 $580,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $255,076 - $347,096	17,200 Added 51.19%	50,800 $959,000
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $36,261 - $53,001	-2,700 Reduced 7.44%	33,600 $641,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $22,906 - $30,602	-1,300 Reduced 3.46%	36,300 $651,000
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $1.32 Million - $1.71 Million	-77,800 Reduced 67.42%	37,600 $763,000
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $908,124 - $1.32 Million	-56,900 Reduced 33.02%	115,400 $2.1 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $49,250 - $89,275	-2,500 Reduced 1.43%	172,300 $3.56 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $950,107 - $1.23 Million	40,900 Added 30.55%	174,800 $4.57 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $360,107 - $788,556	-20,900 Reduced 13.5%	133,900 $3.39 Million
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $3.51 Million - $5.07 Million	-121,200 Reduced 43.91%	154,800 $4.89 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $480,114 - $741,591	-15,300 Reduced 5.25%	276,000 $11.2 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $2.29 Million - $3.21 Million	-85,200 Reduced 22.63%	291,300 $10.2 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $2.05 Million - $3.22 Million	-89,900 Reduced 19.28%	376,500 $10.3 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $646,152 - $1.02 Million	-24,700 Reduced 5.03%	466,400 $13.1 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $943,500 - $1.8 Million	-55,500 Reduced 10.15%	491,100 $12.7 Million
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $5.05 Million - $7.5 Million	294,500 Added 116.82%	546,600 $9.37 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $2.49 Million - $6.5 Million	177,900 Added 239.76%	252,100 $6.24 Million
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $7,901 - $17,352	900 Added 1.23%	74,200 $1.03 Million
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $537,289 - $790,906	73,300 New	73,300 $740,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.05B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account